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Summary
We describe a method for the specific isolation of representative N-terminal peptides
of proteins and their proteolytic fragments. Their isolation is based on a gel-free, peptide-
centric proteomics approach using the principle of diagonal chromatography. We will
indicate that the introduction of an altered chemical property to internal peptides holding a
free -N-terminus results in altered column retention of these peptides, thereby enabling the
isolation and further characterization by mass spectrometry of N-terminal peptides. Besides
pointing to changes in protein expression levels when performing such proteome surveys
in a differential modus, protease specificity and substrate repertoires can be allocated since
both are specified by neo-N-termini generated after a protease cleavage event. As such,
our gel-free proteomics technology is widely applicable and amenable for a variety of
proteome-driven protease degradomics research.
Key Words: Gel-free proteomics; N-terminal COFRADIC; protein processing;
proteases; substrates.
1. Introduction
There are several advantages of gel-free proteomics following selection and
identification of protein N-terminal peptides (1). First, the greatest reduction in
sample complexity prior to mass spectrometry (MS)/MS analysis is achieved
without any loss of information since every protein is represented only by its
N-terminal peptide. Second, as many protein isoforms diverge mainly at their
N-terminal extremities it is possible to distinguish them. As an example, so-
called xenoproteomics experiments, i.e., simultaneous analysis of proteomes
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from different species as present in xenografs, have been performed successfully
using N-terminal peptides (2). Third, newly generated N-termini are indicative
for protein cleavage by proteases, allowing screening for their substrates in a
differential proteomics setup (3). In the protocol to select N-terminal peptides by
COmbined FRActional DIagonal Chromatography (COFRADIC) (4) outlined
below, we focus on this latter application. The commercial rights for this and
other COFRADIC applications belong to pronota (www.pronota.com).
Only a few techniques were reported for analyzing protein N-terminal
sequences in a gel-free, high-throughput manner (5). Two methods somewhat
related to N-terminal COFRADIC were recently reported: the use of protein
sequence tags (6) and positional proteomics (7). However, both methods have
not been applied for proteome-wide characterization of protein processing until
now.
In our approach, following their extraction from cells or tissues, proteins
are reduced, cysteines are alkylated, and free - and -amines are blocked
by trideuteroacetylation, making it possible to later characterize the in vivo
nature (blocked or free, see below) of protein N-termini. Following protein
cleavage this modification is an extra confirmation for the identification of
newly formed N-termini since these should be trideuteroacetylated. As a conse-
quence of this acetylation step, digestion by trypsin results in peptides ending
on an arginine residue. The N-terminal COFRADIC procedure then serves to
separate internal and C-terminal peptides from N-terminal ones. The modifi-
cation reaction between the two sequential and identical chromatographic
separation steps uses 2,4,6-trinitrobenzenesulfonic acid (TNBS). This bulky,
hydrophobic reagent now reacts only with free -amines of internal peptides,
hereby inducing a hydrophobic shift during the secondary separation. In this
way, nonshifted N-terminal peptides (blocked by acetylation) are sorted for
further MS/MS analysis.
To distinguish between different proteomes, stable isotope labeling
is necessary, introducing known measurable peptide mass differences
(Subheading 3.3). Using N-terminal COFRADIC in a differential way, the
dynamics and status of N-terminal modifications on proteins are characterized.
Furthermore, when screening for protease substrates, typically, samples with
and without protease activity are compared. Peptides from newly generated
N-termini will be present only in one proteome sample and will therefore be
present as a peptide with a single isotopic envelope distribution in a mass
spectrum (3). This, together with the trideuteroacetylation step mentioned above,
makes proteome-wide identification and characterization of protease substrates
very straightforward.
Just like other enzymatic systems proteases almost never work alone. They
tend to work in networks in which one protease sequentially activates other
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proteases (e.g., the caspase cascade and during blood clotting), or where
several, different proteases become active at the same time (e.g., release of
proteases by lysosomal membrane permeabilization). Together with unwanted
protease activity induced by cell or tissue lysis, this often complicates the in
vivo study of protease substrates. When used in a differential way, unwanted
protein processing is evident following differential N-terminal COFRADIC
since N-terminal peptides formed by this “unwanted activity” will be equally
present in treated and control samples. Compensating for protease networking
is more difficult and highly challenging, since often there is interest in catego-
rizing the substrates of only one particular protease working in its normal in vivo
environment or network. Therefore, we suggest performing two types of screens.
First, we identify substrates by adding a purified or recombinant protease to a
relevant lysate (further referred to as the in vitro screen) containing substrates in
their native state. The generated list of substrates not only allows the assessment
of cleavage site specificity, but can also be used to validate the results obtained
from the second screen (further referred to as the in vivo screen) where the
protease is active in its biological context. Based on the results of the in vitro
screen those cleavage events in the in vivo screen that are due to activity of the
protease of interest can be assigned.
2. Materials
2.1. Protein Extraction (Subheading 3.1)
1. Jurkat cell line (ATCC, Manassas, VA, #CRL-1658) and RPMI 1640 medium
(Invitrogen, Carlsbad, CA, #61870-010) or adapted arginine-free RPMI medium
(see Subheading 3.3.2).
2. Complete EDTA-free protease inhibitor cocktail tablet (Roche Diagnostics,
Mannheim, Germany, #11873580001).
3. Complete protease inhibitor cocktail tablet (Roche Diagnostics, #11697498001).
4. Lysis buffer 1: 50 mM morpholinoethanesulfonic acid (MES), 50 mM sodium
phosphate, pH 7.4, 150 mM NaCl, 1 mM dithiothreitol (DTT), 1 mM EDTA-free
protease inhibitors (1 tablet per 100 mL of lysis buffer, see Notes 1 and 2).
5. Lysis buffer 2: 50 mM HEPES, pH 7.4, 100 mM NaCl, 0.8% CHAPS, protease
inhibitors (Roche, 1 tablet per 100 mL).
6. Bio-Rad DC Protein Assay Kit (Bio-Rad, Mu¨nchen, Germany #500-0006).
7. Recombinant HIV-1 protease (ProteinOne, Bethesda, MD, #P5102).
8. Disposable desalting columns packed with SephadexTM G-25 (GE Healthcare Bio-
Sciences, Uppsala, Sweden, #17-0853-01, #17-0854-01, or #17-0851-01).
2.2. N-Terminal COFRADIC (Subheading 3.2)
1. Tris(2-carboxyethyl)phosphine (TCEP, Pierce, Rockford, IL, #20490).
2. Iodoacetamide (Fluka BioChemica, Buchs, Switzerland, #57670).
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3. Sulfo-N-hydroxysuccinimide acetate (s-NHS-acetate, Pierce, #26777).
4. Trideutero-N-hydroxysuccinimide acetate (8).
5. Hydroxylamine (Fluka BioChemica, #55458).
6. Hydrogen peroxide (30% [w/w] in H2O, Sigma-Aldrich, St. Louis, MO,#H1009).
7. 2,4,6-Trinitrobenzenesulfonic acid (TNBS, Fluka BioChemika; 1 M solution in
water, #92822).
8. Disposable desalting columns packed with SephadexTM G-25 (GE Healthcare).
9. Sequencing grade modified trypsin (Promega, Madison, WI, #V5111).
10. Analytical reverse-phase high-performance liquid chromatography (RP-HPLC)
column: 2.1 mm internal diameter (i.d.) × 150 mm (length) 300SB-C18 column,
Zorbax R© (Agilent, Waldbronn, Germany).
11. Agilent 1100 Series HPLC system.
12. HPLC grade water (e.g., Baker HPLC analyzed, Mallinckrodt Baker B.V.,
Deventer, the Netherlands).
13. HPLC grade acetonitrile (e.g., Baker HPLC analyzed, Mallinckrodt Baker B.V.).
14. HPLC solvent A: 10 mM ammonium acetate (pH 5.5) or 0.1% trifluoroacetic acid
(TFA) in water/acetonitrile, 98/2 (v/v) (see Note 3).
15. HPLC solvent B: 10 mM ammonium acetate (pH 5.5) or 0.1% TFA in
water/acetonitrile, 30/70 (v/v) (see Note 3).
16. TFA (Rathburn, Walkerburn, UK).
2.3. Protein Isotopic Labeling (Subheading 3.3)
1. 18O-rich water (93.7% H218O [w/w] pure, ARC Laboratories, Apeldoorn, The
Netherlands, #OLM-240).
2. TCEP (Pierce, #OLM-240): prepare a 10 mM stock solution in water.
3. Iodoacetamide (Fluka BioChemica, #57670): prepare a 100 mM stock solution
in water.
4. Guanidinium hydrochloride (Fluka BioChemica, #50939): prepare a 6 M stock
solution in water.
5. Amino acids.
a. 13C6-l-Arginine hydrochloride (Cambridge Isotope Laboratories, Andover,
MA, #CLM-2265).
b. 13C615N4-l-Arginine hydrochloride (Cambridge Isotope Laboratories,
#CNLM-539).
c. l-Arginine (Sigma-Aldrich, #A-8094).
6. Cell culture:
a. Dialyzed fetal bovine serum (Invitrogen, #26400-044).
b. Dulbecco’s modified Eagle’s medium (DMEM), F-12K or RPMI 1640
without l-arginine (Invitrogen). Note: the compositions of these media are
available from Invitrogen as a custom service. The custom-synthesized media
have exactly the same composition as the regular media (DMEM, #21885-
108; RPMI 1640, #61870-010; F-12K, #21127-022 all from Invitrogen),
except that they are deficient of the specified amino acid.
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c. Penicillin–streptomycin (10,000 U of penicillin and 10,000 g/mL of strep-
tomycin) (Invitrogen, #15070-063).
d. HEK 293T cell line (ATCC, #CRL-11268).
e. Jurkat cell line (ATCC, #CRL-1658).
f. K-562 cell line (ATCC, #CCL-243).
g. A-549 cell line (ATCC, #CCL-185).
h. NK-92 cell line (ATCC, #CRL-2407).
i. NK-92MI cell line (ATCC, #CRL-2408).
j. SH-SY5Y cell line (ATCC, #CRL-2266).
7. Prepare concentrated stocks (400 mM) of 13C6, 13C615N4, and 12C6 l-arginine
hydrochloride in phosphate-buffered saline (PBS) (f.c. [final concentration] for
RPMI, #61870; 200 g/mL or 1.15 mM l-arginine or 1.15 mM, f.c.. for F-
12K, #21127; 422 g/mL or 2 mM and f.c. for DMEM, #21885; 84 g/mL
or 0.398 mM) to make complete RPMI 1640 (containing 12C6 l-arginine) and
RPMI 1640 with 13C6 or 13C615N4 l-arginine. Dissolve and divide in small
aliquots to avoid multiple freeze–thaw cycles. Add the optimized amount of stock
13C6, 13C6 15N4, or 12C6 l-arginine hydrochloride to the reconstituted arginine-
deficient RPMI 1640 media (containing 10% dialyzed fetal bovine serum [free
of amino acids], 1% penicillin-streptomycin, and other components whenever
required), as to prepare the heavy and light forms of the media. respectively.
Subsequently, filter the medium through a 0.22-m filter and store it at 4C
until use.
3. Methods
3.1. Extraction Procedures
Efficient protein extraction yielding soluble proteins after disruption of
biological membranes is required prior to N-terminal COFRADIC. Since our
main focus here is the identification of protease substrates, the major differ-
ences between the lysis methods described below depend on whether in vitro
or in vivo substrate catalogues will be constructed. We describe three different
protein extraction procedures preceding differential N-terminal COFRADIC
approaches. Subsection 3.1.1 outlines procedures for in vitro protease substrate
screening whereas Subsection 3.1.2 is recommended for protease-unrelated
studies or studies in which postlytic in vitro enzymatic activity is unwanted.
Both protocols use cells in culture. When starting from dissected animal tissue,
Subsection 3.1.3 must be applied.
For in vitro screens, as many potential substrates as possible must be extracted,
preferably in their native form. In addition, the extraction conditions should be
compatible with subsequent activity of the protease of interest. Therefore, we
suggest extracting proteins by multiple freeze–thaw cycles on the cells of interest
in a buffer optimal for protease activity or adaptable to achieve such condi-
tions. Detergent-based cell lysis is to be avoided since most detergents are ineffi-
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ciently removed and interfere with mass spectrometric analyses. Furthermore,
detergents may lead to protein denaturation and thus to protease access to epitopes
in irrelevant substrates. Also, detergents might influence protease activity.
As a major drawback, some proteins might be missed since their extraction
needs detergents. To avoid contaminating downstream protease activity, broad-
spectrum protease inhibitors against the three classes of proteases other than
the one under investigation should be included, although many proteases are
not well targeted by these inhibitors and behave as exceptions in their class.
For reasons of general protein solubility the pH of the extraction buffer should
be around 7. When studying proteases displaying an acid pH optimum, adjust
the pH of the lysate after its extraction. Ionic strength, chelators, and other
buffer components can best be optimized for each individual protease to reach
its optimal activity.
Since the relevant “library” of possible substrates and specific conditions
for activity differ considerably between proteases, in contrast to an in vivo
screen, we cannot supply an optimal protocol well suited for every protease. As
an example we describe the protein extraction steps and procedures to screen
for substrates of the recombinant HIV-1 protease in a representative lysate of
cultured human Jurkat T cells.
3.1.1. Protein Extraction from Cultured Cells for Subsequent
Protease Incubation
1. a. In the case of metabolic labeling of proteins by 13C6-Arg SILAC: culture Jurkat
cells separately in adapted RPMI 1640 medium in the presence of 12C6 or 13C6-
arginine as described in Subsection 3.3.2. Harvest equal numbers of light and
heavy labeled cells and wash them two times with PBS to remove residual media
components.
b. In the case of postmetabolic, enzymatic labeling of peptides by H182 O after
protein extraction and digestion: harvest the cells cultured in normal RPMI 1640
medium and wash them two times with PBS. Divide the sample in two aliquots of
equal cell numbers. Details with reference to the labeling procedure are outlined
in Subsection 3.3.1.
2. Resuspend individual cell pellets in lysis buffer 1.
3. Freeze both samples by putting them on dry ice for 15 min followed by thawing
on ice at 4C for 15 min. Repeat this step three times.
4. Centrifuge the samples for 15 min at 16,000 × g (4C) and recover the
supernatant.
5. Measure the protein concentration using the Bio-Rad DC Protein Assay Kit
according to the manufacturer’s instructions. Equalize small differences in
protein concentration by diluting the most concentrated sample with the appro-
priate volume of lysis buffer 1.
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6. Acidify both samples with 2 N HCl to pH 5.5 and increase the salt concentration
to 300 mM NaCl using a 5 M stock since the HIV-1 protease has a slightly acid
pH optimum and cleaves more efficiently at higher salt concentrations (9) (see
Note 4).
7. Add to one sample the recombinant HIV-1 protease to a final concentration of 200
nM and incubate for 75 min at 37C (treated sample, see Note 5). Add no protease
or, alternatively, an inactive protease variant to the other sample and incubate
under conditions identical to the treated sample (control sample, see Note 6).
8. After incubation, the protease activity can be blocked by adding an excess of
a potent protease inhibitor to both samples; however, as is the case for the
HIV-1 protease, such (often patented) inhibitors are not always available. In that
case, immediately inhibit any remaining protease activity by adding chaotropes
(e.g., guanidinium hydrochloride) in sufficiently high concentrations (4– 6 M)
combined with cysteine alkylation (see below).
9. The pH of both samples is increased to 7.5 using 2 M NaOH and guanidinium
hydrochloride is added dry to a final concentration of 4 M (see Note 4).
10. Proceed directly to step 2 of Subsection 3.2.1. Mixing of both samples is
discussed in Subsection 3.4.
In screens where extraction conditions do not need to be tuned for monitoring
specific protease activity and the integrity of the three-dimensional structure of
the substrate is unnecessary, postlysis effects due to remaining protease activity
should be avoided during extraction. Below, we describe a general protocol for
protein extraction for in vivo screens starting from cultured cells or dissected
tissue.
3.1.2. Protein Extraction from Cultured Cells
1. In the case of metabolic labeling of proteins by 13C6-Arg SILAC: culture cells
separately in the appropriate medium and in the presence of 12C6 or 13C6-arginine
according to labeling conditions described in Subsection 3.3.2. Perform treatment
of cells during culture (i.e., stimulate cells to evoke protease activity or use as
control) and harvest numbers of light and heavy labeled cells such that equal
amounts of proteins (see Notes 6 and 7) for treated and control cells are obtained.
Wash the cells thoroughly with PBS.
2. In the case of postmetabolic, enzymatic labeling of peptides by H182 O after protein
extraction and digestion: culture the cells in their normal medium, perform appro-
priate treatment of the cells during culture, and harvest numbers of light and heavy
labeled cells to obtain equal amounts of protein (see Notes 6 and 7) for treated and
control sample. Wash the cells thoroughly with PBS.
3. Resuspend each cell pellet in lysis buffer 2 and lyse the cells on ice for 15 min
(see Note 2). More specific protease inhibitors can be added to this lysis buffer if
required.
4. Centrifuge the samples for 15 min at 16,000 × g (4C) and recover the
supernatant.
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5. Measure the protein concentration using the Bio-Rad DC Protein Assay Kit
according to the manufacturer’s instructions. Equalize small differences in concen-
tration by diluting with an appropriate volume of lysis buffer 2.
6. Desalt the protein mixture using disposable desalting columns according to
the manufacturer’s instructions with the appropriate volume of guanidinium
hydrochloride in sodium phosphate (pH 7.5). The final concentration of guani-
dinium hydrochloride should be 4 M after drying down the protein mixture to its
original starting volume.
7. Proceed directly to step 2 of Subsection 3.2.1. Mixing of both samples is discussed
in Subsection 3.4.
3.1.3. Protein Extraction from Dissected Animal Tissue
1. During dissection, wash the tissue samples several times thoroughly with PBS and
remove residual body fluid components as completely as possible. Snap-freeze the
samples in liquid nitrogen and store at –80C until further processing.
2. Subject the frozen tissue to mechanical dissociation by a pestle in a liquid nitrogen-
cooled mortar.
3. Suspend the powder in 4 M guanidinium hydrochloride and 50 mM sodium
phosphate buffer at pH 7.5 (see Note 2).
4. Extract proteins by incubating this suspension on an orbital shaker for 1 h at 4C.
5. Centrifuge the protein sample for 60 min at 90,000 × g and at 4C and recover the
supernatant.
6. Measure the protein concentration using the Bio-Rad DC Protein Assay Kit
according to the manufacturer’s instructions. Equalize small differences in concen-
tration by adding lysis buffer.
7. Proceed directly to step 2 of Subsection 3.2.1. Mixing of both samples is discussed
in Subsection 3.4.
3.2. N-Terminal COFRADIC
3.2.1. Sorting of N-Terminal Peptides
1. Prepare proteomes from treated and control samples as described in
Subheading 3.1.
2. Desalt the protein mixtures on a disposable desalting column according to
the manufacturer’s instructions with the appropriate amount of guanidinium
hydrochloride in sodium phosphate (pH 7.5) to generate a final concentration
of 4 M guanidinium hydrochloride in 50 mM sodium phosphate (pH 7.5) after
vacuum drying the desalted protein mixtures to their original volume.
3. Add freshly prepared TCEP·HCl (1 mM f.c.) and iodoacetamide (2 mM f.c.)
solutions. Let the reduction/alkylation reaction proceed in the dark for 1 h at 37C.
4. Desalt the protein mixtures on a desalting column in 2 M guanidinium
hydrochloride in 50 mM sodium phosphate (pH 8.0) after drying down to its
original volume.
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5. Add freshly prepared 5 mM sulfo-N-hydroxysuccinimide acetate or 10 mM
trideutero-N-hydroxysuccinimide acetate (prepare a fresh 500 mM stock in 1%
DMSO). Incubate for 90 min at 30C.
6. Revert partial acetylation of hydroxyl groups by adding 2 L of hydroxylamine
and incubate for an additional 15 min at 30C.
7. Desalt the mixtures of modified proteins in 20 mMNH4HCO3 (pH 7.6).
8. Reduce the overall volume of each sample to 1 mL by vacuum drying.
9. Boil the protein mixtures for 10 min at 95C and then transfer for 10 min to an
ice bath.
10. Add sequence grade modified trypsin (the enzyme/substrate ratio should be about
1/50) and incubate overnight at 37C.
11. Proceed to step 2 of Subsection 3.3.1 when using differential 18O labeling.
12. Acidify the modified primary fractions by adding 2 L of TFA or 4 l of
100% acetic acid (see Note 8) and centrifuge the peptide mixtures for 10 min at
10,000 × g to remove insoluble material. Transfer the supernatant to an HPLC
sample vial.
13. Add the appropriate volume of 30% (w/v) H2O2 solution to reach a final concen-
tration of 0.5% and incubate for 30 min at 30C (see Note 9).
14. Load the sample on the reverse-phase column (see Subheading 3.2.2) for the
primary COFRADIC separation and fractionate in 12–15 consecutive fractions of
4 min each starting 20 min following sample injection (about 7% of acetonitrile
concentration), as very few peptides elute earlier in the gradient.
15. Dry these primary fractions to complete dryness and redissolve each primary
fraction in 50 L sodium borate buffer (pH 9.5).
16. Add 10 L of a 15 mM TNBS solution and incubate for 1 h at 37C.
17. Repeat the previous step three times to ensure near quantitative TNBS modifi-
cation of free -amino groups.
18. Load the TNBS-treated fraction onto the reverse-phase column, starting with the
most hydrophobic primary fraction, and subsequently fractionate using the same
solvent gradient as during the primary run. Collect the N-terminal peptides (see
Note 10) in 16 equal-volume secondary fractions in an 8-min-long time interval
starting 2 min prior to and ending 2 min after the primary collection interval (see
Note 11). An example of COFRADIC sorting N-terminal peptides is depicted in
Fig. 1.
19. Dry the collected N-terminal peptides and store at –20C until further LC-
MS/MS analysis (see Note 12).
3.2.2. Setting Up the Reverse-Phase Diagonal Chromatographic System
for Sorting N-Terminal Peptides
1. Apply the following binary solvent gradient for separating the peptide mixture:
a. Following injection of the sample onto the column, apply a 10 min isocratic
run with 100% of solvent A at a constant flow rate of 80 L/min (see
Note 13).
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Fig. 1. Sorting of N-terminal peptides. Cultured human Jurkat cells were subjected
to three freeze–thaw cycles to extract proteins and subsequently processed as indicated
under the method in Subsection 3.1.1, step 4. The upper panel shows the RP-HPLC
chromatogram (UV absorbance measured at 214 nm) of the separation of the tryptic
digest of this protein mixture (i.e., the primary COFRADIC run). This peptide mixture
was fractionated into 13 primary fractions of 4 min each (from 20 to 72 min). Shown in
the lower panel is the RP-HPLC chromatogram of secondary fraction 6 after treatment
of the peptide mixture with TNBS (i.e., the secondary COFRADIC run). Unaltered N-
terminal peptides are collected in 16 equal-volume secondary fractions in an 8-min-wide
time window starting 2 min prior to the original, primary elution interval of fraction
6 (indicated in a gray background with a dashed line). TNBS-modified peptides (i.e.,
internal peptides that carried a free -amino group) now obtained a hydrophobic trini-
trophenyl group and are thus shifted to later elution times. Note that background peaks
due to impurities in TNBS are indicated with an asterisk.
b. Apply a linear, binary gradient over 100 min to 100% of solvent B.
c. Apply a 10 min isocratic wash with 100% of solvent B, followed by a linear
gradient over 5 min to 0% of solvent B (100% of solvent A).
d. Reequilibrate the column for another 20 min with 100% of solvent A before
injection of another sample.
2. Depending upon the type of peptide isolated and thus the preceding protein prepa-
ration steps we observed that peptides typically elute between 20 and 100 min of
gradient time, corresponding to acetonitrile concentrations of 7% and 63%, respec-
tively. Collect the primary fractions as indicated in step 13 of Subsection 3.2.1.
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3.3. Differential Quantitative Proteomic Labeling Approaches
Exploited for N-Terminal COFRADIC
When performing large-scale, differential proteomics surveys, labeling
methods incorporating stable, heavy isotopes into proteins or peptides are
typically used. By determining the ratio of the intensities originating from the
isotopically “light” and “heavy” ion signals of a peptide in a mass spectrum, the
relative abundance of the peptide (and protein) in the two represented varieties
can be assessed. Isotope labeling can be done on two different levels: either
through physiological incorporation (metabolic labeling) or by introduction of
a specific enzymatic or chemical derivatization step on the peptide or protein
level (postmetabolic labeling) (10,12,17). Here, we focus on the strategies that
we routinely follow to introduce stable heavy isotopic label(s) when performing
N-terminal COFRADIC, the selection of which mainly depends on the sample’s
origin.
We recently introduced an acetylation step on the protein level introducing a
trideutero-acetyl group (8) on every free -and -amino group. As mentioned
above, cleavage event(s) will now appear as single trideuteroactelyted neo-N-
termini (see Note 14).
Representative for postmetabolic peptide labeling is proteolytic 18O labeling
by trypsin (13). Trypsin catalyzes the exchange of oxygen atoms at the C-
terminal carboxyl groups of tryptic peptides and produces in this way labelled
peptides that carry two oxygen-18 isotopes at their C-termini. This labeling
is introduced following proteome digestion and before chromatographic and
mass spectrometric analyses to identify and quantify (relatively) peptides. The
primary advantage of this labeling approach is that it is applicable to every prote-
olytic digest independent of its origin of sampling, whether tissue extractions,
body fluids, or cell culture lysates.
Routinely, we also use SILAC (stable isotopic labeling of amino acids in cell
cultures; see Note 15). SILAC was developed as a simple and accurate approach
for MS-based quantitative proteomics (14) and relies on the incorporation of
essential amino acids with substituted stable isotopic nuclei (D, 13C, and 15N).
During the N-terminal COFRADIC protocol, except for the majority of the C-
terminal peptides, all peptides end on arginine. Accordingly, heavy form(s) of
arginine are the SILAC amino acids to be used since these will introduce (at
least) one label per peptide. Interestingly, there are at least three benefits when
using 13C6 or 13C615N4 l-arginine. First, the spacing between the light and heavy
isotopes is increased (6 to 10 Da) as compared to oxygen-16/18 labeling making
the determination of abundance ratios straightforward, since peaks are more
easily declustered. Second, SILAC labels are very stable during COFRADIC and
MS experiments in contrast to the oxygen-16/18 labeling where back-exchange
can occur in acidic environments. Finally, triplex experiments may be performed
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since 12C6, 13C6, or 13C615N4 arginine forms can be used. The flow path for both
labeling strategies is illustrated in Fig. 2. One possible flaw is the arginine-to-
proline conversion, which can occur in mammalian cells. This results in label
dilution in two different peptide forms both representing the heavy form of the
peptide (see Fig. 3). Thus far, in our hands, in all cell lines tested (including
primary cell lines), proline conversion occurs but can be reduced to background
levels by reducing the l-arginine concentration to 5–20% of the concentration
suggested by manufacturers of cell media, and this without notably affecting cell
growth and morphological appearances (see Note 16).
3.3.1. Peptide Labeling with Oxygen-18 Atoms
1. Step 2 of this protocol is preceded by step 10 of Subsection 3.2.1.
2. Following digestion in 10 mM ammonium bicarbonate (pH 7.6), vacuum dry
peptide mixtures.
3. Redissolve the peptides in 25 L of 0.1 MKH2PO4 (pH 4.5) and redry.
4. Add 100 L of 18O-rich water (“heavy peptides”) or 100 L of natural water
(“light peptides”) and incubate overnight at 37C.
5. Transfer 10 L of the 10 mM TCEP solution to an Eppendorf tube and vacuum dry.
Add 10 L of the 100 mM iodoacetamide solution to 75 L of 6 M guanidinium
Fig. 2. Schematic strategic experimental outline when making use of diverse quanti-
tative proteomic labeling approaches. As outlined, the flow path for sample processing
differs when making use of either oxygen-18 (A) or SILAC labeling (B). When using
SILAC, samples can be processed simultaneously, ruling out potential artifacts intro-
duced by parallel processing of samples with postmetabolic oxygen-18 labeling. For
oxygen-18 labeling, samples are mixed at the peptide level.
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Fig. 3. SILAC labeling strategy in combination with N-terminal COFRADIC.
(A) The SILAC labeling with 13C6 l-arginine at various points in time. Jurkat cells
were switched to 13C6 l-arginine-containing RPMI medium on day 0 and samples were
obtained on days 0, 1, 2, 3, 4, 5, 6, and 7 during the labeling process. After acety-
lation, lysates were digested with sequencing-grade modified trypsin and separated on
an RP-HPLC. Corresponding fractions in time in the different setups were analyzed
by MALDI-MS. The panels show the extent of incorporation of 13C6 l-arginine into
the peptide at the indicated time points. Complete incorporation of 13C6 l-arginine into
proteins was observed in digests obtained from cell lysates harvested on day 5. (B)
Jurkat cells readily convert 13C6 l-arginine to 13C5 -proline. This results in the formation
of two clusters of heavy peptides differing by 5 Da for all proline-containing peptides.
The correct weight of the heavy peptides is thus the sum of the 13C6 l-arginine and the
13C6 l-arginine + 13C5 -proline peak. By reducing the amount of 13C6 l-arginine, proline
conversion was no longer observed.
hydrochloride (this is for 100 L of 18O-rich water or natural water to achieve an
f.c. for guanidinium hydrochloride of 4 M) in a second Eppendorf tube and dry.
6. Transfer the peptide mixture to the “TCEP vial,” mix thoroughly, and incubate at
37C for 1 h.
7. Transfer the reduced peptide mixture to the “iodoacetamide + Gu.HCl vial” and
incubate again for 1 h at 37C in the dark. At this time point, samples can be stored
at –20C (see Note 17).
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8. Mix both samples in a 1/1 ratio.
9. Continue with step 12 of Subsection 3.2.1.
3.3.2. SILAC Labeling with Heavy Arginine
1. Label the cell population with 13C6, 13C615N4, or 12C6 l-arginine hydrochloride
during cell culture at 37C, 5% CO2 for at least five population doublings (usually
complete incorporation is achieved after six doublings).
2. Harvest cells from each population and extract proteins as outlined in
Subsection 3.1.
3.4. Sample Mixing
For differential proteomics, mixing of peptide samples in a near 1/1 ratio is
favored for meaningful quantification information. As this ratio is based on the
total protein amount present in both samples it is important to start with equal
sample amounts. Also, small differences in total protein concentration after lysis
can be accounted for as indicated in the protocols of Subsection 3.1 to obtain
unavoidable but similar losses of protein material in the following desalting
steps.
For 18O-labeled peptides, the point of sample mixing is fixed in the procedure
(after labeling and before the primary COFRADIC run) as described in
Subsection 3.3.1. As for SILAC-labeled proteins, samples can basically be
mixed as early as possible in the protocol (directly after lysis or even before)
guaranteeing like treatment of samples. However, to avoid postlysis effects
when studying protease substrates it is beneficial to mix samples at a later
time point in the procedure when high chaotrope concentration, alkylation
(e.g., in the case of cysteine proteases or proteases depending on disulfide
bridges for their activity), and acetylation blocked any protease activity. Since
most proteases will have lost their activity after one of the modification
reactions, samples can then be mixed rather safely before subsequent desalting
steps.
In any case, a precise measurement of protein concentration should precede
the mixing step. By mixing different sample volumes it is possible to adjust
for small differences in protein concentration. However, for both 18O-labeled
peptides and SILAC peptides it is preferable to first mix a small part of the
samples in a 1/1 ratio and to use this mixture for a “preprimary” COFRADIC
run. Collected primary fractions of this separation are then measured in
MS mode. Based on the observed average ratio of the peptide peaks, the
mixing volumes of the rest of the samples can be adjusted to obtain a 1/1
ratio.
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4. Notes
1. Besides EDTA, these tablets also lack pepstatin A, a generally used inhibitor for
aspartic proteases.
2. Since the total protein amount after extraction depends on the cell type and the
number of lysed cells or amount of tissue, it is necessary to determine the amount
of protein material harvested. A total protein amount of at least 2 mg when
using a total extract should be obtained. Correct the buffer volume to get a total
protein concentration between 2 and 4 mg/mL taking into account the volume of
sample that needs to be loaded on desalting columns. Several types of columns
are available, differing in the sample volume applied. The same type of columns
should be used during the whole procedure.
3. The elution profile of a peptide depends on the ion pairing agent of the HPLC
solvents. In ammonium acetate systems peptides tend to elute at lower concen-
trations of organic solvent than in TFA systems. For cataloguing proteomes we
suggest using TFA as this ion-pairing agent produces extremely sharp peaks and
as such a high resolution can be obtained when sorting amino terminal peptides.
4. High concentrated stock solutions are used to avoid large decreases in total
protein concentration by volume increase of the sample. The volume of stock
solutions added to a given buffer solution should be tested in advance.
5. The conditions of concentration and time for protease incubation should
be optimized using alternative techniques (e.g., Western analysis of known
substrates to follow their processing in function of time/protease concentration).
During optimization and for the final analysis a constant protein (substrate)
concentration should be respected (see also Note 2).
6. The analysis should be repeated with label swapping between samples. Besides
accounting for an extra validation of substrates from a single experiment,
repeating the analysis will partly overcome the undersampling problem, which
is an intrinsic drawback of mass spectrometers working in automated MS/MS
mode due to random selection of peptide ions for fragmentation.
7. Cell treatment can influence both the amount and nature of proteins extracted
(e.g., lysis of cells in different phases of cell death). Therefore, it is necessary to
determine the extracted protein amount upon stimulation and correct for differ-
ences between treated and control samples.
8. When peptides are labeled with oxygen-18, TFA cannot be used as an ion pairing
ion in HPLC solvents as this may lead to acid-catalyzed exchange of oxygen
atoms in carboxyl groups (13). Typically, acetic acid is first added to lower the pH
to 5 before injecting peptides onto the RP column, which is run in an ammonium
acetate system.
9. The use of hydrogen peroxide to uniformly oxidize methionines to their
sulfoxide form is recommended since this prevents accidental hydrophilic
shifts of methionyl peptides between chromatographic runs. When performing
methionine oxidation prior to the primary RP-HPLC separation (step 9 of
Subsection 3.2.1) it is important to respect the oxidation time (30 min) and
temperature (30C) since prolonged incubation leads to unwanted and uncon-
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trolled oxidation of methionine to methionine sulfone, and the side chain of other
amino acids such as cysteine and tryptophan is also oxidized. This implies that
following the oxidation step it is necessary to proceed immediately with the RP-
HPLC separation of the peptide mixture.
10. Besides N-terminal peptides, other types of peptides are unavoidably cosorted
by COFRADIC. Peptides carrying (or acquiring) a blocked, nonacetylated N-
terminal amino acid such as a pyrrolidone carboxylic acid or a cyclic S-
carbamoylmethylcysteine are cosorted since they do not react with TNBS.
Although they appear to “pollute” the mixture of sorted peptides, for differ-
ential proteomics purposes their presence can be beneficial as several peptides
per protein can be quantified, thus increasing the accuracy of the abundance ratio
of their proteins.
11. In theory, N-terminal peptides should elute in the same time frame during
the primary and secondary runs. In practice, given the fact that HPLC is not
absolutely reproducible, the elution window tends to enlarge and especially
abundant N-terminal peptides tend to smear over larger intervals. Therefore,
peptides are collected both before (2 min) and after (2 min) their primary
collection interval. Since the number of peptides collected in these intervals
is much lower than those collected in the expected elution window, such a
secondary fraction may be pooled reducing the number of LC-MS/MS analyses.
12. To link MS/MS spectra of COFRADIC-sorted peptide ions efficiently to
peptide/protein sequences in databases, search engines such as Mascot (15) need
to consider the (potential) presence of several modifications on the analyzed
peptides. An overview of both the fixed modifications (due to the protein prepa-
ration method) and potential (variable) modifications (modifications that are
likely to be present in [a part of] the sorted peptides) is presented in Table 1.
Furthermore, the sequence of a sorted peptide indicating irreversible protein
processing is often not exactly predicted by search engines as they do not
consider in vivo “processing and ragging” of protein (termini). Hence, identifi-
cation of such peptides may be missed. To overcome such flaws, we constructed
DBToolkit (freely available via http://www.proteomics.be), an algorithm that
uses protein databases as input, imitates protein processing, and creates FASTA-
formatted, peptide databases (16). Using such peptide-centric databases, we
noted an increase of at least 30% of identified MS/MS spectra of N-terminal
peptides using Mascot (3).
13. In the overall COFRADIC setup the reproducibility of peptide separation
is critical. Adequate HPLC instrumentation is now available creating highly
reproducible solvent gradients and thus equally reproducible peptide separations.
We use Agilent’s electronic flow controller for maintaining a constant solvent
flow through the column independent of the backpressure and we thermo-control
as many parts of the system as possible (e.g., the column compartment as well
as the tubing delivering the solvent to the column and the fraction collector).
Taking care of these issues, we generally observe a standard deviation of only a
few seconds on the retention time of peptides in a complex peptide mixture over
a gradient of nearly 2 h.
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Table 1
Recommended Parameters for Searching Databases with MS/MS Spectra of
Peptides Sorted by N-Terminal COFRADIC a
Fixed modifications Variable modifications
Trideutero-acetylation (K) Acetylation (N-terminus)
Carbamidomethyl (C) Trideutero-acetylation (N-terminus)
Oxidation (M) Deamidation (NQ)
Oxidation (M)
Pyrocarbamidomethyl cysteine (C)
Pyroglutamic acid (N-terminal Q)
Optional fixed modifications Optional variable modifications
18O Labeling
18O C-term (double)
SILAC labeling
13C6 l-arginine 13C5 proline*
a Since the COFRADIC sorting chemistries lead to additional modifications on sorted peptides
we here provide an overview of recommended and essential settings of amino acid modifications
when searching databases with engines such as Mascot or SEQUEST.
*Only when proline conversion occurs.
14. Protease substrates are often characterized by only one identified MS/MS
spectrum (“single-hits”). The presence of a trideutero-acetyl group at the -
amino group of peptides, being present in single isotopic forms, the searched
peptide/protein database indicative of the cleavage specificity of the protease of
interest, the internal start position and manual validation of identified MS/MS
spectra that strictly met the criterium of being ranked one, and scoring above
Mascot’s 95% confidence interval score are all making the identification more
confident.
15. SILAC cannot be applied for labeling harvested tissue samples, although
metabolic labeling of intact species (17,18) has been performed.
16. As for some cell lines, the propagation in media containing dialyzed serum
(devoid of all substances less than about 10 kDa) may require some optimization,
meaning supplementing extra growth factors to the serum.
17. To obtain complete trypsin inactivation the combined action of reductive
alkylation under strong denaturing conditions is required.
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